These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39126937)

  • 21. Erratum.
    Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
    Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature.
    Vural EM; van Munster BC; de Rooij SE
    Drugs Aging; 2014 Jun; 31(6):441-51. PubMed ID: 24802882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased urinary level of melatonin as a marker of disease severity in patients with multiple sclerosis.
    Gholipour T; Ghazizadeh T; Babapour S; Mansouri B; Ghafarpour M; Siroos B; Harirchian MH
    Iran J Allergy Asthma Immunol; 2015 Feb; 14(1):91-7. PubMed ID: 25530144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fingolimod for relapsing-remitting multiple sclerosis.
    La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab.
    Laursen JH; Søndergaard HB; Sørensen PS; Sellebjerg F; Oturai AB
    Mult Scler Relat Disord; 2016 Nov; 10():169-173. PubMed ID: 27919484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial.
    Mukhopadhyay ND; Khorasanchi A; Pandey S; Nemani S; Parker G; Deng X; Arthur DW; Urdaneta A; Del Fabbro E
    Oncologist; 2024 Feb; 29(2):e206-e212. PubMed ID: 37699115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial.
    Sanoobar M; Eghtesadi S; Azimi A; Khalili M; Khodadadi B; Jazayeri S; Gohari MR; Aryaeian N
    Nutr Neurosci; 2015 May; 18(4):169-76. PubMed ID: 24621064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 12-week melatonin supplementation improved dynamic postural stability and walking performance in persons living with multiple sclerosis: A randomized controlled trial.
    Jallouli S; Ghroubi S; Damak M; Sakka S; Elleuch MH; Mhiri C; Yahia A; Driss T; de Marco G; Hammouda O
    Behav Brain Res; 2025 Jan; 476():115191. PubMed ID: 39122092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
    Kappos L; Li DK; Stüve O; Hartung HP; Freedman MS; Hemmer B; Rieckmann P; Montalban X; Ziemssen T; Hunter B; Arnould S; Wallström E; Selmaj K
    JAMA Neurol; 2016 Sep; 73(9):1089-98. PubMed ID: 27380540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
    Selmaj K; Li DK; Hartung HP; Hemmer B; Kappos L; Freedman MS; Stüve O; Rieckmann P; Montalban X; Ziemssen T; Auberson LZ; Pohlmann H; Mercier F; Dahlke F; Wallström E
    Lancet Neurol; 2013 Aug; 12(8):756-67. PubMed ID: 23764350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic review.
    Morsali S; Sabahi Z; Kakaei J; Hakimzadeh Z; Hamidi S; Gholipour-Khalili E; Sanaie S; Talebi M; Naseri A
    Inflammopharmacology; 2023 Oct; 31(5):2213-2220. PubMed ID: 37429996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility study to assess lesion repair in relapsing-remitting multiple sclerosis: A randomized controlled pilot clinical trial of domperidone add-on treatment.
    Zhang Y; Liu WQ; Hosseinpour Z; Pike GB; Cerchiaro G; Greenfield J; Yong VW; Metz LM
    Mult Scler Relat Disord; 2024 May; 85():105525. PubMed ID: 38461731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results.
    Wilken J; Traboulsee A; Nelson F; Ionete C; Kolind S; Fratto T; Kane R; Gandhi R; Rawlings AM; Roesch N; Ozog MA; DeLuca J;
    Mult Scler Relat Disord; 2023 May; 73():104677. PubMed ID: 37028124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.
    Røsjø E; Steffensen LH; Jørgensen L; Lindstrøm JC; Šaltytė Benth J; Michelsen AE; Aukrust P; Ueland T; Kampman MT; Torkildsen Ø; Holmøy T
    J Neurol; 2015 Dec; 262(12):2713-21. PubMed ID: 26429571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.